Merck: successful subcutaneous version of Keytruda
(CercleFinance.com) - On Tuesday, Merck announced the success of a Phase III trial involving subcutaneous administration of its flagship immunotherapy Keytruda, in the treatment of a form of bronchial cancer.
The study, which combined Keytrud with a hyaluronidase variant developed by Alteogen, met its primary endpoint by demonstrating non-inferiority to intravenous infusion of the same solution, its conventional mode of administration.
The trial involved patients with metastatic non-small cell cancer.
Merck describes the results as "very encouraging", since the subcutaneous version of the treatment can be administered in just two to three minutes, which the laboratory believes improves patient comfort.
Copyright (c) 2024 CercleFinance.com. All rights reserved.
The study, which combined Keytrud with a hyaluronidase variant developed by Alteogen, met its primary endpoint by demonstrating non-inferiority to intravenous infusion of the same solution, its conventional mode of administration.
The trial involved patients with metastatic non-small cell cancer.
Merck describes the results as "very encouraging", since the subcutaneous version of the treatment can be administered in just two to three minutes, which the laboratory believes improves patient comfort.
Copyright (c) 2024 CercleFinance.com. All rights reserved.